UP!

AMAG $9.54   View long term graphs

AMAG Pharmaceuticals Inc.
Type
Public
Traded as NASDAQ: AMAG
S&P 600 Component
Industry Pharmaceutical Industry
Founded November 9, 1981 (1981-11-09)
Headquarters United States
Products Pharmaceutics
Website www.amagpharma.com
Footnotes / references
Founded

AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company listed on NASDAQ under the symbol "AMAG".

In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.

AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of US$71,500,000 in 2013.

In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.

In June 2015 the company acquired Cord Blood Registry for $700 million.

In 2014 AMAG acquired Lumara Health, formerly KV Pharmaceutical Company.

In 2015, the company's revenue reached $418 million. AMAG had 552 employees.

The company's research and tests focus on iron deficiency anemia and related intravenous drugs.

In June 2009, the company's main product Ferumoxytol, an oral medication used on adult patients with chronic kidney disease, was approved by US Food and Drug Administration.

In December 2011, Health Canada approved Ferumoxytol, under the brand name Feraheme, for use in treating both dialysis and non-dialysis dependent chronic kidney disease patients, as well as for treatment of adult patients suffering from iron deficiency anemia.

From 2010 to 2014, AMAG had a distribution agreement with Takeda which granted them exclusivity to the Canadian and European Union markets, where the drug is sold under the brand names Feraheme and Rienso, respectively.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-02 Future report Set alerts
Q3 2020 2020-10-30 Future report Set alerts
Q2 2020 2020-08-06 -0.23 -0.39
Q1 2020 2020-05-11 -0.30 -0.66
Q4 2019 2020-03-04 -0.35 -5.89
Q3 2019 2019-11-01 -0.42 -0.70
Q2 2019 2019-08-07 -0.87 -3.58
Q1 2019 2019-05-07 -0.90 -3.56
Q4 2018 2019-02-07 -0.60 -0.60
Q3 2018 2018-11-01 -1.88 -1.88

Ratings

2016-06-08 Reiterated Rating Jefferies Group Buy
2016-06-02 Reiterated Rating Jefferies Group Buy
2016-05-09 Lower Price Target Deutsche Bank Hold $42.00 to $35.00
2016-05-09 Lower Price Target Deutsche Bank AG Hold $42.00 to $35.00
2016-05-05 Reiterated Rating JPMorgan Chase & Co. Hold $37.00
2016-05-04 Lower Price Target Leerink Swann Outperform $45.00 to $40.00
2016-05-04 Downgrade Raymond James Outperform to Market Perform
2016-05-04 Reiterated Rating Jefferies Group Buy
2016-05-04 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2016-04-16 Reiterated Rating Leerink Swann Outperform
2016-03-28 Lower Price Target Robert W. Baird Outperform $26.00 to $25.00
2016-03-28 Lower Price Target Leerink Swann Outperform $25.00 to $23.00
2016-03-28 Downgrade Ladenburg Thalmann Buy to Neutral
2016-03-28 Upgrade Jefferies Group Underperform to Hold $16.00 to $19.00
2016-02-18 Lower Price Target Guggenheim Buy $54.00 to $51.00
2016-01-28 Initiated Coverage Northland Securities Outperform $40.00
2016-01-21 Initiated Coverage Barclays Equal Weight $32.00
2016-01-21 Initiated Coverage Barclays PLC Equal Weight $32.00
2016-01-14 Lower Price Target Deutsche Bank Hold $43.00 to $42.00
2016-01-03 Reiterated Rating Jefferies Group Buy
2015-12-28 Reiterated Rating Jefferies Group Buy $70.00
2015-12-10 Reiterated Rating Leerink Swann Outperform $71.00 to $45.00
2015-11-19 Lower Price Target Deutsche Bank Hold $50.00 to $43.00
2015-11-12 Reiterated Rating Jefferies Group Buy $28.95 to $70.00
2015-11-04 Lower Price Target Deutsche Bank Hold $58.00 to $50.00
2015-11-04 Lower Price Target Jefferies Group Buy $80.00 to $70.00
2015-11-02 Boost Price Target Robert W. Baird Outperform $54.00 to $55.00
2015-09-23 Reiterated Rating Leerink Swann Buy
2015-09-18 Reiterated Rating Jefferies Group Buy $80.00
2015-09-11 Reiterated Rating Leerink Swann Buy $85.00
2015-09-03 Initiated Coverage Deutsche Bank Hold $75.00 to $71.00
2015-08-31 Initiated Coverage Raymond James Outperform $75.00
2015-08-27 Boost Price Target Guggenheim Buy $85.00 to $89.00
2015-08-18 Initiated Coverage Jefferies Group Buy $80.00
2015-06-25 Reiterated Rating Deutsche Bank Hold $75.00
2015-06-12 Initiated Coverage Deutsche Bank Hold $75.00
2015-06-08 Initiated Coverage Guggenheim Buy $85.00
2015-05-18 Boost Price Target Leerink Swann Outperform $60.00 to $85.00
2015-05-06 Boost Price Target JPMorgan Chase & Co. Neutral $41.00 to $51.00
2015-05-06 Boost Price Target Leerink Swann Outperform $54.00 to $60.00
2015-03-09 Initiated Coverage Cowen and Company Outperform
2015-02-11 Set Price Target Jefferies Group Buy $55.00
2015-01-26 Reiterated Rating FBR & Co. Market Perform $42.00
2015-01-26 Reiterated Rating FBR & Co Market Perform $42.00
2015-01-16 Boost Price Target Jefferies Group Buy $40.00 to $55.00
2015-01-12 Reiterated Rating JPMorgan Chase & Co. Hold $39.00 to $41.00
2014-12-02 Reiterated Rating JPMorgan Chase & Co. Neutral $22.00 to $39.00
2014-09-30 Upgrade Jefferies Group Hold to Buy $21.00 to $40.00
2014-09-30 Upgrade FBR & Co. Market Perform to Outperform $21.00 to $36.00
2014-08-13 Initiated Coverage FBR & Co. Market Perform $21.00
2014-01-23 Lower Price Target Summer Street Buy $30.00
2014-01-23 Upgrade Jefferies Group Underperform to Hold $16.00 to $19.00
2014-01-22 Downgrade Ladenburg Thalmann Buy to Neutral
2013-10-24 Reiterated Rating Summer Street Buy $31.00 to $43.00
2013-10-18 Upgrade Robert W. Baird Neutral to Outperform $25.00 to $26.00
2013-09-30 Lower Price Target Ladenburg Thalmann Buy $27.00 to $25.00
2013-06-10 Reiterated Ladenburg Thalmann Buy $25 to $23
2012-07-26 Reiterated Ladenburg Thalmann Buy $15 to $17.50
2012-05-17 Upgrade Ladenburg Thalmann Neutral to Buy $15
2012-05-10 Downgrade Robert W. Baird Outperform to Neutral $21 to $17
2012-05-10 Downgrade Ladenburg Thalmann Buy to Neutral
2011-10-24 Upgrade Ladenburg Thalmann Neutral to Buy $18 to $18
2011-06-30 Reiterated Ladenburg Thalmann Neutral $18.50 to $20
2010-10-29 Reiterated Ladenburg Thalmann Neutral $24 to $15.50
2010-10-29 Downgrade Canaccord Genuity Buy to Hold $52 to $19
2010-09-21 Reiterated Ladenburg Thalmann Neutral $38.50 to $24
2010-07-29 Downgrade Robert W. Baird Outperform to Neutral $40 to $36
2010-01-12 Upgrade Citigroup Hold to Buy
2009-12-17 Reiterated Robert W. Baird Outperform $60 to $55
2009-10-05 Downgrade Jefferies & Co Buy to Hold $60 to $44
2009-09-10 Downgrade Citigroup Buy to Hold
2009-09-01 Reiterated Ladenburg Thalmann Buy $69 to $60
2009-07-01 Reiterated Jefferies & Co Buy $55 to $60
2016-06-08 Reiterated Rating Jefferies Group Buy
2016-06-02 Reiterated Rating Jefferies Group Buy
2016-05-09 Lower Price Target Deutsche Bank Hold $42.00 to $35.00
2016-05-09 Lower Price Target Deutsche Bank AG Hold $42.00 to $35.00
2016-05-05 Reiterated Rating JPMorgan Chase & Co. Hold $37.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
ADAGE CAPITAL PARTNERS GP LLC 11.60%  (2546592) ADXS / AMAG / BDBD / CALA / FPRX / HTWR / IGOI / PBYI / PSUN / PTGX /
HEIDEN WILLIAM K President & CEO 1.61%  (353015) AMAG / ATRA /
THOMAS FRANK E CFO, COO, Interim CEO 0.63%  (138195) AMAG /
Grund Nicholas Chief Commercial Officer 0.30%  (66324) AMAG /
Caffe Steven SVP, Ch. Dev. and Reg. Officer 0.27%  (59400) AMAG /
Bolgiano Elizabeth Scott Chief Human Resources Officer 0.26%  (56918) AMAG /
Townsend Scott B SVP, General Counsel 0.26%  (56851) AMAG /
Holmes Scott A Chief Accounting Officer 0.24%  (53304) AMAG / KERX /
Myles Edward H Chief Financial Officer 0.24%  (53294) AMAG /
Vittiglio Joseph SVP, General Counsel 0.24%  (52854) AMAG / AVEO /
Krop Julie SVP Clinical & Regulatory, CMO 0.24%  (51636) AMAG /
Edward P. Jordan SVP, Sales and Marketing 0.18%  (39213) AMAG /
Butcher James Alan EVP, Chief Business Officer 0.13%  (28418) AMAG /
White Christopher G Chief Business Officer and SVP 0.13%  (28400) AMAG /
NARACHI MICHAEL 0.11%  (23900) AMAG / CLDN / OREX /
Wilson Kenneth H SVP, Sales and Marketing 0.11%  (23387) AMAG /
SCOON DAVEY 0.10%  (21935) AMAG / BIOD / OFIX /
Russell Lesley 0.10%  (21335) AMAG / ECYT / ENTA / TLOG /
SANTINI GINO 0.09%  (19510) AMAG / HZNP / ICPT / VTAE /
Madison Greg EVP, Chief Commercial Officer 0.09%  (18800) AMAG / KERX /
Crouse Geoffrey EVP 0.09%  (18750) AMAG /
PEREZ ROBERT J 0.08%  (17535) AMAG / CBST /
Fallon John A. 0.07%  (15399) AMAG / EXAS / PODD /
DE SILVA RAJIV 0.07%  (14822) AMAG / ENDP /
Deptula Barbara 0.07%  (14660) AMAG /
SULAT JAMES R 0.06%  (13127) AMAG / MNTA /
KELLEY BRIAN P 0.03%  (5571) AMAG / APRN / GMCR /
ALLEN LEE F MD PhD Chief Medical Officer and EVP 0.01%  (2229) AMAG / ARGS / SPPI /

Comments